Myeloma Beacon Introduces New Service For Tracking Postings At Myeloma-Related Blogs
The Myeloma Beacon is pleased to announce an important new service offering. Starting today, visitors to the website can use the Beacon’s new “blog posting aggregator” to track postings at a wide range of multiple myeloma-related blogs. The aggregator provides excerpts from, and links to, blog postings by multiple myeloma patients, caregivers, and family members around the world.
“The Beacon’s blog posting aggregator is a convenient way for our readers to keep tabs on all the popular myeloma-related blogs,” explains Maike Haehle, associate publisher of The Myeloma Beacon. “By checking the aggregator once or twice a day, Beacon readers can stay up-to-date with everything going on in the myeloma blogosphere.”
Hundreds of times every day, the blog posting aggregator checks actively maintained blogs in the Beacon’s comprehensive directory of multiple myeloma blogs.
When the aggregator finds a new posting at a blog that it is monitoring, the title, publication date, and excerpt of the posting are added to the aggregator database. This information can then be viewed by Beacon readers on the aggregator’s pages, which are easily accessible via the "Blogs" link in the Beacon's top menu.
Postings on the aggregator pages are displayed based on publication date and time, with the most recently published postings shown first.
The blog posting aggregator is yet another service The Beacon is introducing to ensure that The Beacon continues to be one of the Internet’s leading resources for staying abreast of myeloma-related news and events. Together with the Beacon’s myeloma discussion forum, regularly updated news, patient and caregiver columns, and physician columns, the aggregator service rounds out a unique set of content and services that has made The Beacon into a regular destination for thousands of members of the myeloma community.
If you are a myeloma patient, caregiver, or family member and you would like your blog to be among those monitored by the Beacon’s blog posting aggregator, feel free to use the blog submission link at the bottom of each blog aggregator page or at the Beacon’s directory of multiple myeloma blogs.
Related Articles:
- Latest Myeloma Research To Be Presented At The American Society Of Clinical Oncology Annual Meeting (ASCO 2018)
- Researchers Shed More Light On Risk Of MGUS In Close Relatives Of People With Multiple Myeloma
- ASCO 2018 Update – Expert Perspectives On The Key Multiple Myeloma-Related Oral Presentations
- Dr. Christoph Driessen On Nelfinavir In The Treatment Of Multiple Myeloma
- Eyelid-Related Complications Of Velcade Therapy: New Insights And Recommendations
I love your new Blog feature. It's now so easy to keep up to date with the blogs I like to follow. Thanks.
Very Cool!
Can you please eopen it up worldwide. I am in NZ and took the list of all the current trials what they were, where they were, and the 'experts' had never heard of any of them, and said NONE were available in New Zealand. We have recently had Velcade added to the public health availability.
If we can see what is happening and where, then we have a choice to go to another country for participation in a trial, IF we know where they are.
Is this possible? Cannot see why not.
Also all our tests are in different mesasurements.
My lgG is 29, and Americans ask me what my spike is.
I have no idea. Can we have a chart with the different measurements wo we can evaluate our progress, and where we are on the stage 1 11, 111 etc.
Queria informacion sobre las anomalias cromosomaticas del(6p21)y si esta presencia puede implicar presencia minima de enfermedad
Esto se presento luego de recibir 6 ciclos de VAD.
Mi diagnostico es MM tipo Kappa IgG EC III, 53 años, Varon
Gracias
[Rough translation: Looking for information about chromosomal anomality del(6p21) and if its presence may indicate minor presence of disease. This occurs after receiving 6 cycles of VAD. My diagnosis is IgG Kappa MM EC type III, age 53.]
del(6p21) as an isolated abnormality would be very unusual for myeloma and likely does not represent minimal disease. Translocation of 6p21 with 14q32 summarized t(6;14)(p21;q32) is seen in about 6% of patients with myeloma, and would represent minimal disease.
[Beacon Staff note: Dr. Bergsagel is Professor of Medicine at the Mayo Clinic.]